Literature DB >> 31670285

The association of matrix metalloproteinas-2 promoter polymorphisms with lung cancer susceptibility in Taiwan.

Guan-Liang Chen1, Shou-Cheng Wang2, Te-Chun Shen3, Chia-Wen Tsai3, Wen-Shin Chang3, Hsin-Ting Li3, Cheng-Nan Wu4, Che-Yi Chao5, Te-Chun Hsia3, Da-Tian Bau6.   

Abstract

Matrix metalloproteinases-2 (MMP2) has been reported to be overexpressed in various types of cancer. However, the contribution of various genotypes of MMP2 to lung cancer is controversial and not yet been examined in Taiwan. Therefore, in the current study, we investigated the association of MMP2 genotypes with lung cancer risk among Taiwanese. In this hospital-based, case-control study, 358 lung cancer patients and 716 age- and gender-matched healthy controls were recruited, and the genotypic distributions of MMP2-1306 and MMP2- 735 were determined. Then, their association with lung cancer was evaluated, and their interaction with personal smoking status was also examined via stratification analysis. The results showed that the percentages of variant CT and TT at MMP2-1306 were 17.3% and 1.7% among the lung cancer patients, respectively, much lower than those of 28.7% and 2.4%, respectively, among the healthy controls (P for trend = 0.0001). The allelic frequency distribution analysis showed that the variant T allele at MMP2-1306 conferred a statistically significantly lower lung cancer risk than the wild-type C allele (adjusted odds ratio = 0.54, 95% confidence interval = 0.41-0.72, P = 0.0001). There was an obvious effect of MMP2-1306 genotype on lung cancer risk among the subpopulations of ever smokers but not nonsmokers. As for the genotypes of MMP2-735, there was no such differential distribution in the aspects of genotypic or allelic frequencies, or combinative effects with smoking status. The genotypes of MMP2-1306 may act as a biomarker in determining personal susceptibility to lung cancer in Taiwan. The contribution of MMP2 genotypes alone and its joint effects with personal cigarette smoking habit on lung cancer susceptibility should be taken into consideration of the clinical practices for early detection and prediction of lung cancer in Taiwan.

Entities:  

Keywords:  Genotype; Taiwan; lung cancer; matrix metalloproteinase-2; polymorphism; smoking

Mesh:

Substances:

Year:  2019        PMID: 31670285     DOI: 10.4103/CJP.CJP_43_19

Source DB:  PubMed          Journal:  Chin J Physiol        ISSN: 0304-4920            Impact factor:   1.764


  5 in total

1.  Association of Murine Double Minute 2 Genotypes and Lung Cancer Risk.

Authors:  Yu-Chao Lin; Wen-Shin Chang; Te-Chun Shen; Hsin-Ting Li; Chia-Hsiang Li; Yu-Chen Hsiau; Yun-Chi Wang; Cheng-Nan Wu; Chi-Li Gong; Zhi-Hong Wang; Chia-Wen Tsai; Te-Chun Hsia; DA-Tian Bau
Journal:  In Vivo       Date:  2020 May-Jun       Impact factor: 2.155

2.  Epidemiological Evidence Between Variants in Matrix Metalloproteinases-2, -7, and -9 and Cancer Risk.

Authors:  Chenglu Huang; Suqin Xu; Zhilin Luo; Dong Li; Rui Wang; Tianhu Wang
Journal:  Front Oncol       Date:  2022-04-28       Impact factor: 5.738

3.  The Significant Interaction of Excision Repair Cross-complementing Group 1 Genotypes and Smoking to Lung Cancer Risk.

Authors:  Li-Hsiou Chen; Te-Chun Shen; Chia-Hsiang Li; Kuo-Liang Chiu; Yu-Chen Hsiau; Yun-Chi Wang; Chi-Li Gong; Zhi-Hong Wang; Wen-Shin Chang; Chia-Wen Tsai; Te-Chun Hsia; DA-Tian Bau
Journal:  Cancer Genomics Proteomics       Date:  2020 Sep-Oct       Impact factor: 4.069

4.  Significant Association of MMP2 Promoter Genotypes to Asthma Susceptibility in Taiwan.

Authors:  Li-Hsiou Chen; Kuo-Liang Chiu; Te-Chun Hsia; Yen-Hsien Lee; Te-Chun Shen; Chia-Hsiang Li; Yi-Cheng Shen; Wen-Shin Chang; Chia-Wen Tsai; DA-Tian Bau
Journal:  In Vivo       Date:  2020 Nov-Dec       Impact factor: 2.155

5.  Correlation between MMP2 expression in lung cancer tissues and clinical parameters: a retrospective clinical analysis.

Authors:  Liping Han; Baowei Sheng; Qingdi Zeng; Wei Yao; Qiufang Jiang
Journal:  BMC Pulm Med       Date:  2020-10-28       Impact factor: 3.317

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.